USFDA issues EIR to Medak facility of Suven Life Sciences

Gayathri Udyawar
/ Categories: Trending, Markets

Suven Life Sciences Limited received Establishment Inspection Report (EIR) from US drug regulator for its Pashamylaram, Medak facility.

The USFDA conducted the inspection in February 2018. The regulator certified that the manufacturing facility complies with the standards of Current Good Manufacturing Processes (cGMP). The company has filed 19 Drug Master Files and 5 ANDAs from this facility.

Suven Life Sciences is a bio-pharma company based in Hyderabad based. The company manufactures and supplies APIs (bulk drugs), intermediates and formulations under cGMP. It is a leading manufacturer under Contract Research and Manufacturing Services (CRAMS) and Drug Discovery and Development program.

Meanwhile at 14:55 hours, the stock of Suven Life Sciences was quoting Rs. 190.65 per share, up by 5.19 per cent on Monday.

 

Rate this article:
3.0

Leave a comment

Add comment

DSIJ MINDSHARE

Mkt Commentary19-Apr, 2024

IPO Analysis19-Apr, 2024

Multibaggers19-Apr, 2024

Mindshare19-Apr, 2024

Mindshare19-Apr, 2024

Knowledge

Technical19-Apr, 2024

General18-Apr, 2024

Technical18-Apr, 2024

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR